Please ensure Javascript is enabled for purposes of website accessibility

Bill Ackman Broke His Own Rules Investing in Valeant Pharmaceuticals

By Alex Dumortier, CFA - Apr 20, 2016 at 3:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Billionaire investor Bill Ackman could have avoided a $2 billion loss on Valeant Pharmaceutcals International, if he had just followed his own investing rules.

High-profile activist investor Bill Ackman has been in the headlines recently -- but not in the way he'd prefer. The collapse in the share price of one of his top holdings, Valeant Pharmaceuticals International (BHC 1.25%), from its August high has saddled his Pershing Square funds with an unrealized loss that is estimated to have reached $2 billion. What went wrong?

Source: Insider Monkey, republished under CC BY-ND 2.0.

For one thing, he didn't follow his own principles, as outlined in his letter to his investors. If he had, he never would have made the investment in the first place, and he wouldn't have let his losses snowball to such proportions.

Long Investments
"As a general rule," Ackman said, "we purchase simple, predictable, free-cash-flow-generative businesses that have sustainable competitive advantages due to brand power, unique assets, long-term contractual arrangements, or other factors. These companies are [generally] modestly or negatively leveraged (i.e., have more cash than debt) and do not need access to the capital markets to survive and thrive."

In his September 2009 presentation on Valeant at the Ira Sohn conference, Ackman introduced the concept of the "platform company" into which he tried to shoehorn Valeant:

"Businesses managed by superior operators that execute value-enhancing acquisitions and shareholder-focused capital allocation have substantial platform value."

It's now becoming increasingly clear that Valeant had no problem finding and executing value-destroying deals.

Ackman could not have known this with certainty at the time he made his investment, but there were certainly signs available to a professional investor doing in-depth due diligence, which Ackman is famous for.

While it's true that pharmaceutical companies are not the easiest businesses to understand, Valeant's acquisitiveness made it very difficult to assess the underlying growth and profitability. (The company didn't facilitate this, either.)

With that type of uncertainty, why did Ackman attribute the positive characteristics of a platform company to Valeant? My guess is that he allowed the stock and its phenomenal performance to convince him of the merits of the company instead of the merits of the company convincing him to own the stock. You can't argue with success, right?

Valeant also fails the "modestly or negatively leveraged" test. At the time at which Ackman made his first investment in Valeant, the company was already significantly indebted. By the end of the third quarter of 2015, net debt stood at nearly $30 billion.

To pursue its acquisition strategy, Valeant absolutely needed "access to the capital markets in order to survive and thrive," failing another Ackman criterion for long investments.

Valeant was incapable of financing its acquisitions internally like a proper platform company, such as Warren Buffett's Berkshire Hathaway -- to which Ackman had the nerve to compare Valeant.

On retaining the option to abandon
I consider one of our investment strengths to be our willingness to promptly change our mind when confronted with new information which is inconsistent with our original investment thesis," Ackman said. "I have learned from prior experience that sometimes the better part of valor in an investment situation is to move on."

There is quite a bit of new information that has surfaced about Valeant -- most of it negative -- that obliterates the original thesis.

Valeant's strategy, conceived and executed by CEO J. Michael Pearson, is irreparably broken, and the company has renounced. How's that for new information?

Pearson, who is leaving Valeant as soon as his replacement is found, said last October that price increases in 2016 would be modest, and while the company might be involved in acquisitions in the near future, it would be as a seller, not a buyer.

Of course, it's always possible that Ackman has since developed a new thesis, but one thing is certain: It isn't the platform company.

Confidence and humility in investing
"I have learned that the key to long-term success in investing is to balance confidence with the humility to recognize when the facts are no longer consistent with one's original investment thesis," Ackman said.

In this instance, it appears Ackman tipped the wrong end of the balance, misplacing confidence over humility. And it has cost him dearly.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bausch Health Companies Inc. Stock Quote
Bausch Health Companies Inc.
$9.70 (1.25%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.